$6 billion AstraZeneca and I3 are once again working together to develop antibody conjugate drugs.

On July 27, AstraZeneca and Daiichi Sankyo reached a new global development and commercialization agreement with Daiichi Sankyo on targeting the human nourishing layer cell surface glycoprotein antigen 2 (TROP2) antibody coupling (ADC) DS-1062.
DS-1062 is a potentially heavy-impact new drug that promises to redefine the standard of treatment for lung, breast cancer and many other cancers.
DS-1062 is currently being developed to treat a variety of tumors expressing TROP2, which is overexpressed in most non-small cell lung cancer syllaves and breast cancers.
the agreement, AstraZeneca will pay a total of $1 billion in installments: $350 million when the agreement is completed, $325 million 12 months after the agreement takes effect, and $325 million 24 months after the agreement takes effect.
will pay up to $1 billion in additional amounts once the drug is successfully approved for market, and up to $4 billion in sales-related milestones.
the two companies will jointly develop and commercialize DS-1062 worldwide, in addition to Japan, and the first three companies will retain the right to develop exclusively in Japan.
the cooperation agreement entered into force on 27 July 2020.
The first three will manufacture and supply the DS-1062.
a successful partnership between AstraZeneca and I3 in ADC drug development.
a $6.9 billion partnership in March 2019 for the ADC drug Enhertu (fam-trastuzumab deruxtecan-nxki, DS-8201), which was approved by the FDA in December 2019 to treat patients who cannot remove or metastatic HER2 breast cancer."
DS-1062 is a combination of antibody coupling drugs developed using proprietary DXd ADC technology, made up of monoclonal antibodies that target the Trop2 protein and connect stogens to DXd.
TROP2 is a transmembrane glycoprotein that is highly expressed in a variety of solid tumors, including NSCLC.
optimization of the coupling technique for synthetic DS-1062 makes its drug antibody ratio (DAR) largely, improving its safety.
currently, DS-1062 is being developed for the treatment of NSCLC, etc. "We see great potential for this antibody drug conjugate in lung cancer and in breast cancer and other cancers that express TROP2," said Pascal Soriot, chief executive officer of AstraZeneca,
(Photo: First Three).
we are pleased to have this new partnership with First Three and build on the successful launch of Trastuzumab Deruxtecan to further expand our product line and leadership in the field of oncology.
We now have six potential bombshells in the field of oncology, and more in our early and late pipelines. "The DS-1062 is an ADC on our leading DXd ADCs technology platform and has the potential to be the best 2 ADC for a wide range of tumors, including lung and breast cancer," said Sunao Manabe, President and CEO of the
.
this new strategic partnership with AstraZeneca will enable us to deliver DS-1062 to more patients worldwide as quickly as possible.
we will work together to design and implement research and development strategies to maximize the value of the DS-1062, as we did with our previous collaboration with Enhertu.
"DS-1062 is a potential new drug that has not been approved for any indications in any country.
Note: The purpose of this paper is to introduce the progress of medical and health research, not the recommended treatment plan.
if you need guidance on a treatment plan, go to a regular hospital.
References: astraZeneca and Daiichi Sankyo into the collaboration to the development and commercialise new antibody drug conjugate. Retrieved 2020-07-27, from.